Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Revenue (2018 - 2025)

Sunshine Biopharma's Revenue history spans 9 years, with the latest figure at $8.6 million for Q4 2025.

  • For Q4 2025, Revenue fell 10.61% year-over-year to $8.6 million; the TTM value through Dec 2025 reached $36.3 million, up 4.11%, while the annual FY2025 figure was $36.3 million, 4.11% up from the prior year.
  • Revenue reached $8.6 million in Q4 2025 per SBFM's latest filing, down from $9.4 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $9.6 million in Q4 2024 to a low of $40058.0 in Q1 2021.
  • Average Revenue over 5 years is $5.0 million, with a median of $5.8 million recorded in 2023.
  • Peak YoY movement for Revenue: surged 4528.68% in 2022, then dropped 10.61% in 2025.
  • A 5-year view of Revenue shows it stood at $85118.0 in 2021, then soared by 4528.68% to $3.9 million in 2022, then surged by 94.94% to $7.7 million in 2023, then increased by 24.93% to $9.6 million in 2024, then decreased by 10.61% to $8.6 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Revenue are $8.6 million (Q4 2025), $9.4 million (Q3 2025), and $9.4 million (Q2 2025).